/stocks — the workspaceLOADING
All KLRS SEC filings, by type → · Earnings date & implied move · Search inside filings
Kalaris Therapeutics, Inc. (KLRS) is a biological products, (no diagnostic substances) company. 2 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-11 from KLRS's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind KLRS’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from KLRS’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
Not reported in XBRL for this filer.
A plain-English read on KLRS plus an auto-SWOT — built from KLRS's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate KLRS using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has KLRS been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as KLRS tagged it: net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
The fair-value line is KLRS’s own median P/E, P/S, P/B and P/FCF applied to each year’s fundamentals — the price its typical valuation would have implied. Where the solid line sits above the dashed one, the stock traded at a premium to its own history that year; below, a discount. This is a description of past valuation, computed from KLRS’s filings and price history — not a forecast and not investment advice. A stock can trade above or below its own median for years.
Projected from KLRS's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentKLRS files or announces.
KLRS has rallied after 3 of its last 6 earnings reports.
Each figure is one earnings reaction — how much KLRS moved from the closing price the day before a report to the close the day after. Based on its last 6 reports.
Large earnings reactions have been common.
KLRS has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+8.9% and -14.5%).
A more typical earnings reaction has been approximately ±7.0%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-11 | +0.0% |
| 2026-05-12 | +2.1% |
| 2026-03-17 | -14.5% |
| 2025-11-12 | +5.1% |
| 2025-08-13 | -8.8% |
| 2025-05-14 | +8.9% |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No lawmaker has disclosed a trade in KLRS under the STOCK Act.
Total return including reinvested dividends, from KLRS’s adjusted closing prices. Past return is not a forecast and not investment advice.
None of the 5 estimators could run on KLRS's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for KLRS. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No sector peer set is priced for KLRS, so sector medians could not fill the gaps.
Every refusal recorded for KLRS → · How often we decline, and why →
No tracked institution reported a position in KLRS in the latest 13F round.
| AKKARAJU SRINIVASDirector | BUY | $1.2M | view → |
1 of the 2 checks that ran found nothing new for KLRS; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Berkeley Heights, New Jersey, United States · the company’s charter and its head office are in different states.
Source: the cover page of Kalaris Therapeutics, Inc.’s 10-Q filed 2026-08-11, on EDGAR. Filings checked 2026-10-27. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works